Canada’s Drug Agency (CDA-AMC) recommends that Enhertu be reimbursed by public drug plans for the second-line treatment of adult patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti–HER2-based regimen for a time-limited period while additional evidence is generated if certain conditions are met.
